Lily Morris was diagnosed with acute lymphoblastic leukaemia (ALL) in 2022 aged 15. Now 16, she tells us about its impact on her GCSE preparations, and the support she’s received from her school and friends as she transitioned back into full-time education.
Charlotte Bowling's daughter, Amelie, was diagnosed with acute lymphoblastic leukaemia (ALL) in June 2019 aged six. Charlotte tells us about the support her daughter and her family received from her school, including an innovative way of ensuring Amelie was involved even when not physically present.
Parents and carers of children who have been diagnosed with cancer often have many questions about school and education. Keeley McEvoy, Lead Assistant Headteacher of the Medical Needs Teaching Service working at Leeds Children’s Hospital, explains more about what to expect from hospital teaching, ongoing education support and transitioning back to school.
Dr. Ren Manias, Consultant Paediatric Oncologist at Southampton General Hospital, explains that while a cancer diagnosis impacts a child's learning, various support options—including hospital schools, home tutoring, and remote learning—are available to help maintain educational continuity and emotional wellbeing during and after treatment.
Children with cancer who also have learning difficulties and autism often have additional needs when it comes to their care. Jeanette Hawkins, CCLG’s Chief Nurse, tells us more about a project aiming to improve support for this group of patients.
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Pritesh Patel, Senior Specialist Pharmacist in Paediatric Cancer at Great Ormond Street Hospital for Children and CCLG member
Caroline Brown, Lead Complementary Therapist for Paediatrics, Teenagers and Young Adults at The Royal Marsden Hospital
Gareth Veal, Professor of Cancer Pharmacology at the Newcastle University Cancer Centre, leads a team helping doctors to personalise treatments through an innovative process called ‘therapeutic drug monitoring’. Here, he tells us more about his work.
